Innate Immunotherapeutics

Innate Immunotherapeutics Limited is a medical biotechnology company with offices in Sydney and Auckland.
The Company is currently conducting a Phase 2B efficacy trial of its drug candidate (MIS416) in patients with secondary progressive multiple sclerosis (SPMS). There are currently no safe and effective ongoing treatments for this progressive and highly disabling form of multiple sclerosis.
On completion of this study, expected 2017, the Company’s strategy is to partner this clinical programme application with ‘big pharma’ to complete approval trials and launch sales into the worldwide unmet market for SPMS. 

Latest Media Releases

Innate Immunotherapeutics Limited, Trading Halt

16/03/2017 08:32:00

The securities of Innate Immunotherapeutics Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by th…

Latest News